<DOC>
	<DOCNO>NCT02237079</DOCNO>
	<brief_summary>The goal pilot clinical study perform randomize placebo-controlled study assess beneficial effect 3 month-treatment Bazedoxifene/Conjugated Estrogens ( BZA/CE ) vs. placebo glucose homeostasis body composition 20 post-menopausal woman . The recruitment perform Tulane Health Sciences Center .</brief_summary>
	<brief_title>Bazedoxifene/Conjugated Estrogens ( BZA/CE ) Improvement Metabolism ( BIM )</brief_title>
	<detailed_description />
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<criteria>Postmenopausal woman ( &lt; 5y since final menstrual period ) age 5060y Symptomatic ( hot flash , vaginal dryness ) asymptomatic BMI 2645 kg/m2 ( Overweight , Obesity I Obesity II ) Fasting glucose &lt; 125mg/dl Triglycerides &lt; 200mg/dl Normal mammogram within past 12 month Physician clearance Amenorrhea cause ( Hyperandrogenemia anovulation ) type 2 type 1 diabetes Medications : diabetes diabetic drug , dyslipidemia , estrogen/progestin therapy , antidepressant antipsychotic , antiretroviral ( HIV ) , oral steroid , weight loss drug â‰¤ 3 month washout birth control pill ( often prescribe postmenopausal symptom ) Hysterectomy ( partial complete ) Contraindications estrogen treatment ( unusual vaginal bleeding , blot clot , hepatic disease , bleed disorder , past/present history breast uterine cancer , pregnant , breastfeed )</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>